Jennifer Doudna, the co-developer of CRISPR, says there’s a “coming revolution” in climate-adapted crops and animals.

A feud between Prime Medicine and Tessera Therapeutics, two gene-editing companies, has spilled out into public.

The company reported promising third-quarter 2024 results, highlighting the IND clearance and the approved study design for a phase III trial of their in vivo gene editing therapy, nex-z (NTLA-2001), ...

Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

Spanish biotech Integra Therapeutics has upped its arsenal of gene editing tools by licensing Caszyme’s Cas12I nucleases, the ...

The CRISPR tool is capable of repairing the genetic defect responsible for the immune disease chronic granulomatous disease.

We recently published a list of 10 Most Promising Gene Editing Stocks to Buy According to Hedge Funds. In this article, we ...

Analyst Mitchell Kapoor from H.C. Wainwright reiterated a Buy rating on Verve Therapeutics (VERV – Research Report) and decreased the ...

Using state-of-the-art technology, researchers have identified several specific steps needed for CRISPR to become active and perform its gene editing function. These preclinical findings could lead to ...

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

Calm considered adult conversation."Gareth Edgecombe believes this is needed as New Zealand prepares to lift the blanket ban ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...